- Home
- CASS vs SAGE Comparison
CASS vs SAGE Comparison
Compare CASS & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- SAGE
- Stock Information
- Founded
- CASS 1906
- SAGE 2010
- Country
- CASS United States
- SAGE United States
- Employees
- CASS 1209
- SAGE N/A
- Industry
- CASS Business Services
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- SAGE Health Care
- Exchange
- CASS Nasdaq
- SAGE Nasdaq
- Market Cap
- CASS 535.4M
- SAGE 462.2M
- IPO Year
- CASS 1996
- SAGE 2014
- Fundamental
- Price
- CASS $39.46
- SAGE $7.44
- Analyst Decision
- CASS Buy
- SAGE Hold
- Analyst Count
- CASS 1
- SAGE 20
- Target Price
- CASS $45.00
- SAGE $11.39
- AVG Volume (30 Days)
- CASS 47.7K
- SAGE 2.1M
- Earning Date
- CASS 01-23-2025
- SAGE 02-12-2025
- Dividend Yield
- CASS 3.14%
- SAGE N/A
- EPS Growth
- CASS N/A
- SAGE N/A
- EPS
- CASS 1.68
- SAGE N/A
- Revenue
- CASS $220,027,000.00
- SAGE $106,399,000.00
- Revenue This Year
- CASS N/A
- SAGE N/A
- Revenue Next Year
- CASS $5.32
- SAGE $122.32
- P/E Ratio
- CASS $23.53
- SAGE N/A
- Revenue Growth
- CASS 4.97
- SAGE 837.60
- 52 Week Low
- CASS $37.99
- SAGE $4.62
- 52 Week High
- CASS $50.25
- SAGE $27.68
- Technical
- Relative Strength Index (RSI)
- CASS 36.44
- SAGE 69.28
- Support Level
- CASS $38.01
- SAGE $5.45
- Resistance Level
- CASS $41.71
- SAGE $7.88
- Average True Range (ATR)
- CASS 1.07
- SAGE 0.40
- MACD
- CASS -0.16
- SAGE 0.20
- Stochastic Oscillator
- CASS 34.12
- SAGE 84.23
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.